The Promise of a New Alzheimer’s Drug

Since the time Alzheimer’s disease was discovered, scientists have debated the causes of cognitive decline. Lately, pharmaceutical companies have been in the news for possible treatment options for the WORD disease.

Lecanemab, which will be marketed as Leqembi, received accelerated F.D.A. approval earlier this year. Eisai, the pharmaceutical company responsible for Lecanemab, has applied for full F.D.A. approval.

Other drugs are in the pipeline, including mRNA vaccines, therapies targeting brain plaque, and drugs repairing dysfunctional protein processing. As a result, doctors and scientists are hopeful about the possibility of preventing symptoms or at least slowing them down enough that most people will not get dementia in their lifetime.

For more information see Sue Halpern “The Promise of a New Alzheimer’s Drug” The New Yorker, February 7, 2023.

Special thanks to Lewis Saret (Attorney, Washington, D.C.) for bringing this article to my attention. 

https://lawprofessors.typepad.com/trusts_estates_prof/2023/04/the-promise-of-a-new-alzheimers-drug.html